Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Status:
Recruiting
Trial end date:
2025-05-10
Target enrollment:
Participant gender:
Summary
Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or
BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have
activity in patients with homologous recombination defects (HRD).